Adventures in radiosynthesis of clinical grade [68Ga]Ga-DOTA-Siglec-9

Meeri Käkelä; Pauliina Luoto; Tapio Viljanen; Helena Virtanen; Heidi Liljenbäck; Sirpa Jalkanen; Juhani Knuuti; Anne Roivainen; Xiang-Guo Li

doi:10.1039/c7ra12423f

Adventures in radiosynthesis of clinical grade [⁶⁸Ga]Ga-DOTA-Siglec-9

RSC Adv. 2018 Feb 20;8(15):8051-8056. doi: 10.1039/c7ra12423f. eCollection 2018 Feb 19.

Authors

Meeri Käkelä¹, Pauliina Luoto², Tapio Viljanen¹, Helena Virtanen¹, Heidi Liljenbäck^{1

3}, Sirpa Jalkanen⁴, Juhani Knuuti^{1

2}, Anne Roivainen^{1

2

3}, Xiang-Guo Li^{1

5}

Affiliations

¹ Turku PET Centre, University of Turku FI-20521 Turku Finland xiali@utu.fi anne.roivainen@utu.fi.
² Turku PET Centre, Turku University Hospital FI-20521 Turku Finland.
³ Turku Center for Disease Modeling, University of Turku FI-20014 Turku Finland.
⁴ MediCity Research Laboratory and Department of Medical Microbiology and Immunology, University of Turku FI-20014 Turku Finland.
⁵ Turku PET Centre, Åbo Akademi University FI-20521 Turku Finland.

Abstract

We finally managed to establish a protocol for generating Good Manufacturing Practice (GMP)-grade gallium-68-labelled 1,4,7,0-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated sialic acid-binding immunoglobulin-like lectin 9 motif containing peptide ([⁶⁸Ga]Ga-DOTA-Siglec-9), the first radiopharmaceutical for positron emission tomography imaging of vascular adhesion protein 1.